Alevo

Quick links to important sections

Alevo

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alevo

What is Alevo? (Levofloxacin Overview)

Property Description
Active ingredient Levofloxacin Hemihydrate
Forms Film-coated Tablet, Infusion, Ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic (Third-Generation)
General purpose Combating bacterial infections
Origin Synthetic (Optically active S-isomer)

Alevo is a synthetic, prescription-only antibacterial medicine used to manage various bacterial infections by directly eliminating the causative pathogens. The drug’s core active ingredient is Levofloxacin, which is recognized globally for its role in the fluoroquinolone antibiotic class.

Levofloxacin is chemically distinguished as the pure, optically active S-isomer derived from the older, racemic drug ofloxacin. This structural specificity provides a key advantage, as pharmacological studies have confirmed that this form is often more potent than its predecessor. The molecule is stereochemically stable, ensuring reliable efficacy throughout treatment. This mechanism makes Levofloxacin a powerful, broad-spectrum agent for stopping bacterial proliferation.

The single active ingredient product is presented in multiple pharmaceutical preparations, including the film-coated tablet for oral consumption and a solution for infusion for systemic treatment. The availability of these distinct dosage form(s) ensures that Levofloxacin can be administered via the optimal route of administration depending on the infection’s severity and location.

Regulatory References

  1. Levofloxacin entry in WHO Essential Medicines List (eEML)

What side effects are possible with Alevo?

Possible Side Effects and Safety Information

Alevo (levofloxacin) is associated with serious, potentially disabling, and irreversible adverse reactions that primarily affect the musculoskeletal and nervous systems. Because of these risks, the drug's use is restricted by regulatory authorities for certain less severe infections where alternative treatments are available.

Serious and Clinically Significant Adverse Reactions

Discontinue use immediately and seek medical attention if symptoms of the following serious reactions occur:

  • Tendinitis and Tendon Rupture: Risk is increased in older adults (ge 60 years) and those taking corticosteroids. Tendon damage, including the Achilles tendon, can occur during or several months after treatment.
  • Peripheral Neuropathy: Symptoms include pain, burning, tingling, numbness, or weakness in the arms or legs, which may become permanent.
  • Central Nervous System (CNS) Effects: Reactions include seizures, confusion, hallucinations, anxiety, insomnia, depression, and memory problems.
  • Aortic Damage: Risk of aortic aneurysm and dissection (tearing of the aorta) is increased, particularly in older patients.
  • Hepatotoxicity: Severe, potentially fatal liver injury has been reported.
  • Hypersensitivity: Serious, sometimes fatal, allergic reactions (e.g., anaphylaxis, severe skin reactions like Stevens-Johnson syndrome) may occur, often after the first dose.
  • Exacerbation of Myasthenia Gravis: Use is contraindicated due to risk of worsening muscle weakness.

Common Adverse Reactions

The most commonly reported side effects (occurring in ge 3% of patients) are primarily gastrointestinal and CNS-related, including nausea, headache, diarrhea, insomnia, constipation, and dizziness.

Safety Restrictions and Monitoring

Alevo is generally contraindicated in patients with a history of hypersensitivity to any fluoroquinolone and in those with Myasthenia Gravis. Caution is advised in patients with a history of epilepsy, known QT interval prolongation, or renal impairment. Due to the risk of photosensitivity, exposure to strong sunlight and ultraviolet light must be avoided.

Overdose and Emergency Response

Alevo (levofloxacin) overdose is documented by regulatory authorities to involve severe manifestations primarily affecting the central nervous system (CNS) and the cardiovascular system.

Documented Overdose Presentations

Acute toxicity may present with severe CNS effects, including convulsions (seizures), tremors, dizziness, confusion, and hallucinations. Cardiovascular risks include electrical instability, specifically the prolongation of the QT interval on an ECG, which can potentially lead to the life-threatening arrhythmia Torsade de pointes. Severe outcomes such as fatal hepatotoxicity have been associated with high-level exposure.

When to Seek Urgent Medical Help

Regulatory labeling dictates that immediate medical attention is required upon the observation of specific severe symptoms. This includes the sudden onset of a seizure, any sign of tendon rupture (e.g., pain, inability to bear weight), or clinical signs suggesting liver injury, such as jaundice. In such scenarios, the product must be discontinued immediately as part of the initial emergency response.

Overdose Management

There is no specific antidote known for levofloxacin overdose. Management is officially described as symptomatic and supportive treatment, with emphasis on maintaining appropriate hydration. Procedures may include gastric emptying. The official documentation notes that the drug is not efficiently removed by hemodialysis or peritoneal dialysis. Patient observation and required monitoring, particularly of cardiac electrical activity, are necessary due to the risk of QTc prolongation. Special consideration regarding overdose risk is noted for older patients and those with pre-existing renal impairment.

Therapeutic Uses of Alevo

Alevo: Uses and Treated Conditions

Alevo (levofloxacin) is a prescription medicine utilized in the management of specific bacterial infections. It is generally reserved for use when other, safer treatment options are not available, due to the potential for serious adverse effects associated with this class of medication.

The medicine is indicated for the treatment of various bacterial conditions, including respiratory tract infections such as certain types of pneumonia and acute bacterial exacerbation of chronic bronchitis. It is also used to treat infections of the urinary system, specifically complicated and uncomplicated urinary tract infections (UTIs), as well as acute pyelonephritis (a type of kidney infection).

Other therapeutic applications include infections of the skin and soft tissues, chronic bacterial prostatitis, acute bacterial sinusitis, and certain serious public health threats such as post-exposure prophylaxis for inhalational anthrax and treatment of plague.

Quick Facts

  • Primary Therapeutic Domains: Respiratory, Urinary Tract, Skin/Soft Tissue, and Prostate Infections.
  • Serious Public Health Indications: Post-exposure inhalational anthrax and plague.

Patients should consult a healthcare professional to understand the risks and benefits of the drug for their specific condition.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Alevo (levofloxacin) eligibility is governed by official restrictions from regulatory bodies like the FDA and EMA due to the serious risks associated with the fluoroquinolone class.

Contraindications (Must Not Use)

Population/Condition Restriction Regulatory Basis
Allergy Hypersensitivity to levofloxacin, other quinolones, or any excipients. SmPC/FDA
History of Tendon Disorder Related to prior fluoroquinolone use. SmPC/FDA
Epilepsy Use is prohibited. SmPC
Myasthenia Gravis Use must be avoided due to risk of exacerbation. FDA
Pregnancy/Lactation Contraindicated (EU) or not generally recommended (US). SmPC/FDA

Eligible and Restricted Populations

  • Adults ( 18 years): Generally eligible for approved infections.
  • Pediatric Use: Generally not indicated for routine infections due to musculoskeletal risk. Use is restricted to life-threatening conditions like Inhalational Anthrax and Plague in children 6 months of age.
  • Renal Impairment: Requires mandatory dose adjustment when creatinine clearance is leq 50 mL/min to prevent drug accumulation, as Alevo is primarily cleared by the kidneys.
  • Older Adults ( 60 years): Eligible but have an increased risk of severe tendinopathy, especially if using corticosteroids.

What should I know about interactions with other medicines?

Alevo Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Alevo (levofloxacin) based strictly on governmental regulatory sources.

Documented Interaction Classifications

Interaction Type Interacting Agent(s) Regulatory Constraint
Absorption Blockade Multivalent Cation-Containing Products (Antacids, Iron, Zinc, Sucralfate) Oral administration must be separated by at least two hours to prevent significantly reduced levofloxacin absorption.
Pharmacokinetic Increase Probenecid, Cimetidine These agents reduce levofloxacin's renal clearance, leading to higher systemic exposure (increased plasma concentrations).
Pharmacodynamic Enhancement Vitamin K Antagonists (e.g., Warfarin) Requires monitoring of coagulation tests (PT/INR) due to the risk of enhanced anticoagulant effects and bleeding.
Pharmacodynamic Risk Drugs that Prolong the QT Interval (e.g., certain antiarrhythmics, macrolides) Co-administration is contraindicated due to the additive risk of QT interval prolongation.
Metabolic Interference Antidiabetic Agents (e.g., insulin) Requires careful monitoring of blood glucose due to the potential for severe disturbances (hypo- or hyperglycemia).

Additional Constraints

Official regulatory documents note that the interaction between levofloxacin and corticosteroid use carries an increased risk of tendinitis and tendon rupture, particularly in elderly patients (generally those over 60 years of age). For intravenous administration, the product should not be co-administered in the same IV line with solutions containing multivalent cations.

Mechanism of Action

Targeting Bacterial DNA Gyrase and Topoisomerase IV

Alevo’s active component, levofloxacin, enters susceptible bacterial cells and acts as an inhibitor of two essential enzymes: DNA gyrase and Topoisomerase IV. These enzymes are critical for managing the physical structure of the bacteria’s genetic material, specifically the processes of unwinding, copying, and repairing its DNA. This interaction occurs at the enzyme-DNA complex.

The Bactericidal Cascade: From DNA Breakage to Loss of Viability

By binding to and stabilizing the enzyme-DNA complex, the substance prevents the bacterial DNA strands from being rejoined after they are broken. This leads to numerous, irreversible double-stranded DNA breaks throughout the bacterial genome. This extensive damage initiates a molecular cascade that prevents bacterial growth and division, resulting in the loss of cell viability (bacterial death). This physiological consequence contributes to the reduction of the susceptible bacterial load.

Dosage and Administration Information

Administration Routes and Standard Dosing

Alevo (levofloxacin) is formally administered via oral (tablet and solution), intravenous (IV), and ophthalmic routes, a structure allowing for systemic or topical treatment options. The standard systemic usage pattern for adults is once daily (every 24 hours), with single daily doses ranging from 250 mg to 750 mg. The specific dose, treatment duration (which can vary from 3 to 60 days), and the required frequency pattern (once daily for adults, twice daily for select pediatric indications) are strictly defined for the condition being addressed.


Procedural Requirements and Timing

The official instructions outline specific requirements for oral intake: tablets may be taken without regard to food, but the oral solution must be taken either one hour before or two hours after a meal. A strict procedural constraint requires separating all oral formulations from products containing multivalent cations (like antacids) by at least two hours. For IV administration, the solution must be given via slow infusion, requiring 60 minutes for the 500 mg dose and an extended 90-minute period for the 750 mg dose.


Population and Schedule Adjustments

Official instructions mandate specific dose adjustments for adult patients with moderate to severe renal impairment (Creatinine Clearance < 50 mL/min). This modification typically involves reducing the dose or extending the interval to every 48 hours. Should a dose be missed, guidance instructs taking it as soon as possible unless the next dose is scheduled within the next eight hours, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alevo (Levofloxacin)

This overview describes the nature of the official research evidence that has explored the use of Alevo (levofloxacin). It focuses solely on the types of studies conducted, the populations included, and what outcomes were monitored, without providing clinical advice or treatment interpretations.


Evidence for Use in Urinary Tract and Kidney Infections

The research examining the use of Levofloxacin for complicated urinary tract infections (cUTI) and acute pyelonephritis (a type of kidney infection) primarily involves Randomized Controlled Trials (RCTs) and systematic reviews. These studies was evaluated in adult populations, including those with systemic signs of infection or conditions requiring initial intravenous therapy.

Outcomes monitored were related to physical discomfort and systemic or functional imbalance, described as clinical status. Researchers also closely monitored microbiological measurement, which is the assessment of the specific bacterial pathogen, both immediately after the end of the treatment period and during an intermediate follow-up period (7 to 30 days post-therapy).

What remains uncertain relates to the long-term status of these infections, as long-term outcomes are not fully established. Increasing rates of antimicrobial resistance in common urinary pathogens is a subject of ongoing scientific review.


Evidence for Use in Respiratory Tract Infections

The evidence base for community-acquired pneumonia (CAP) and acute bacterial exacerbation of chronic bronchitis (ABECB) includes controlled clinical trials and observational cohort studies, primarily focusing on adults categorized by infection severity.

Research examined clinical status, defined by the monitoring of acute symptoms, and microbiological measurement, defined by the assessment of the identified bacteria. In severe CAP studies, outcomes included measures like all-cause mortality and hospital stay length. Official guidance often discusses this medicine as being used when alternative agents are unsuitable. Long-term data beyond the immediate post-treatment window are not well characterized in large-scale studies.


Evidence for Special Public Health Indications

The evidence structure for indications like post-exposure prophylaxis for inhalational anthrax is distinct. Efficacy data is not derived from human clinical trials, but is observed in controlled animal efficacy studies. Human studies were evaluated to examine the medicine's concentration in the blood, an outcome related to determining whether target levels were measured to correspond with measured levels observed in the animal models. These data show patterns related to plasma concentration, which serves as a surrogate marker.


What Research Gaps and Uncertainty Exist

Overall, the evidence base presents several limitations. The increasing emergence of bacteria that are resistant to this class of antibiotics is a major, ongoing scientific concern. Furthermore, for many indications, there is limited information for long-term outcomes or the durability of the effect beyond the immediate post-treatment assessment. Research examining treatment durations beyond 14 days in pediatric patients remains limited in available trials.

Key Studies & References Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI (Guideline context for cUTI/pyelonephritis, resistance concern)

Frequently Asked Questions (FAQ)

Common questions about Alevo (FAQ)


Q: Can Alevo be taken with common over-the-counter pain relievers?

A: Official information indicates a potential interaction between Alevo and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen. This combination may increase the risk of central nervous system stimulation or seizures. Interactions with other classes of non-NSAID pain relievers are not typically detailed in the core regulatory documents.


Q: Are there any major food or drink restrictions while using Alevo?

A: Alevo tablets can generally be taken with or without food. However, official instructions recommend separating all oral forms of Alevo by at least two hours from products containing multivalent cations, such as antacids, iron, and zinc supplements. This separation is required to prevent these products from significantly blocking the absorption of Alevo.


Q: Is Alevo safe to take if I have a sensitive stomach?

A: Common adverse effects reported in regulatory documents include various gastrointestinal issues such as nausea, diarrhea, and constipation. Severe or persistent diarrhea is a symptom that has been reported and should be discussed with the prescribing healthcare provider, as it may be a sign of a more serious infection.


Q: Does Alevo interact with blood thinners like warfarin?

A: Yes, regulatory documents confirm an interaction with blood thinners classified as Vitamin K antagonists, such as warfarin. This interaction may enhance the anticoagulant effect and increase the risk of bleeding. Official guidance notes that co-administration requires careful monitoring of coagulation tests, like PT/INR.


Q: What are the signs of an allergic reaction to Alevo that I should look out for?

A: Serious hypersensitivity reactions have been reported, sometimes immediately after the first dose. Regulatory information lists signs such as rash, hives, swelling of the face or throat, difficulty swallowing or breathing, and a rapid heartbeat. These symptoms represent a serious reaction and warrant immediate attention from a healthcare provider.


Q: Can Alevo cause issues with heartburn or acid reflux?

A: Common gastrointestinal side effects listed in the product information include nausea, diarrhea, and constipation. While these issues are documented, heartburn or acid reflux are not typically listed among the most commonly reported adverse reactions for Alevo.


Q: Is Alevo used to treat fever as well as pain?

A: Alevo is a fluoroquinolone antibacterial, meaning its purpose is to treat specific infections caused by susceptible bacteria. It is not approved or indicated for the general treatment of fever or pain, which are typically addressed by different classes of medication.


Q: Are there any natural supplements that are known to interact with Alevo?

A: Official information recommends separating Alevo from supplements that contain multivalent cations, such as iron, zinc, or calcium, due to the risk of impaired drug absorption. Specific interactions with herbal or other natural supplements are not routinely detailed in the core regulatory drug label.


Q: What is the difference in how Alevo works compared to ibuprofen?

A: Alevo is an antibiotic that works by entering bacterial cells and stopping them from growing and dividing by disrupting their DNA. This is a mechanism fundamentally different from pain relievers like ibuprofen, which function by blocking the body's inflammatory response.


Q: How much research is available comparing Alevo to a placebo?

A: The efficacy and safety of Alevo are supported by clinical studies detailed in the product label. These studies often include Randomized Controlled Trials (RCTs) which typically use a placebo group to accurately measure the drug's effectiveness for specific indications like sinusitis or pneumonia.


Q: What is the main function of the inactive ingredients in Alevo tablets?

A: The inactive ingredients are included to form the physical tablet and ensure its proper function. They act as fillers, binders, coatings, and coloring agents, but they do not contribute to the medicine's primary antibacterial action.


Q: Is it normal to feel a bit dizzy after taking Alevo?

A: Yes, regulatory documents indicate that dizziness is one of the most common adverse reactions reported in patients taking Alevo. It is considered a known potential side effect of the medicine.


Q: What kind of studies have been done on the long-term use of Alevo?

A: Alevo is typically prescribed for courses of therapy lasting days or weeks. Regulatory bodies have issued warnings about potentially disabling and long-lasting side effects affecting the tendons, muscles, and nerves that can occur even after treatment is complete. The focus of most regulatory studies is on the immediate post-treatment period.


Q: Why do doctors prescribe Alevo instead of just recommending ibuprofen sometimes?

A: Alevo is a prescription antibiotic used solely to treat specific bacterial infections, such as certain types of pneumonia or urinary tract infections. Ibuprofen is used only to manage pain and inflammation. Alevo is prescribed when a bacterial cause of illness is identified and requires targeted elimination.


Q: Can I take Alevo on an empty stomach?

A: Yes, Alevo tablets can be taken without regard to food, meaning they can be taken on an empty stomach. However, the liquid oral solution has specific instructions that require it to be taken either one hour before or two hours after a meal.


Q: Do I need a prescription to get Alevo?

A: Yes, Alevo (levofloxacin) is legally classified as a prescription-only medicine and cannot be purchased over-the-counter.


Q: What is the maximum number of days in a row someone should take Alevo?

A: The duration of treatment is strictly defined by the condition being addressed and can vary widely, from a few days for minor infections to up to 60 days for very specific, severe public health indications.


Q: Is Alevo known to affect liver function?

A: Regulatory documents include a warning regarding hepatotoxicity, which is the potential for severe, sometimes fatal, liver injury. If symptoms of liver injury occur, the regulatory guidance is to discontinue the medicine and seek immediate medical attention.


Q: Is it okay to drink alcohol while using Alevo?

A: While regulatory labels may not list a direct contraindication, warnings are present regarding central nervous system effects (like dizziness and confusion) and blood sugar disturbances. Because alcohol consumption may worsen these effects, this should be reviewed with the prescribing healthcare provider.


Q: How soon after taking Alevo can I take another dose?

A: The standard systemic dosing schedule for Alevo in adults is typically once daily, meaning approximately every 24 hours. The specific time interval between doses is strictly determined by the prescribed schedule for the infection being treated.


Q: What is the difference between Alevo and other common NSAIDs?

A: Alevo is an antibiotic that operates by killing bacteria via disrupting their DNA copying and repair processes. In contrast, NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) act by blocking the body's chemical pathways that signal pain and cause inflammation.


Q: Does Alevo affect kidney function?

A: Yes, Alevo is primarily eliminated from the body through the kidneys. Regulatory documents require that the dose must be adjusted for patients with reduced kidney function (renal impairment) to prevent the drug from accumulating in the body.


Q: Is the side effect profile different for the prescription strength of Alevo versus the over-the-counter version?

A: Alevo is a prescription-only medication; therefore, no approved over-the-counter version exists. The side effect profile described in the regulatory documents applies to all prescription strengths of the drug.


Q: Why might a person's body stop responding to Alevo over time?

A: Official information warns that bacteria can develop resistance to antibiotics, including Alevo, if the medicine is prescribed unnecessarily. This means that the targeted bacteria may mutate and stop responding to the drug's effects, a major public health concern.


Q: Are there specific patient groups that should avoid Alevo completely?

A: Yes, Alevo is officially contraindicated and must not be used in certain patients. This includes individuals with a known allergy or hypersensitivity to Alevo or any other quinolone antibiotic, and those with the neuromuscular disease Myasthenia Gravis.


Q: Does Alevo have a sedative effect?

A: Central nervous system effects are reported in regulatory data, including dizziness and insomnia (difficulty sleeping). While insomnia suggests an activating effect, a direct sedative effect is not listed among the most common adverse reactions for Alevo.

How should Alevo be stored and disposed of?

Alevo (levofloxacin) tablets must be stored according to strict regulatory guidelines to maintain potency and stability.

Storage Requirements

Alevo is required to be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F), with limited excursions allowed up to 30 C (86 F). The product must be protected from excessive heat, moisture, and direct light. It is prohibited to freeze the tablets. The medicine must be kept in a tightly closed container and stored securely out of the reach of children.

Disposal Instructions

Unused or expired Alevo should be disposed of properly through a drug take-back program. Levofloxacin is not on the U.S. Food and Drug Administration's list of medicines recommended for flushing. If a take-back program is unavailable, the drug should be mixed with an undesirable substance, placed in a sealed container, and thrown away in the household trash, in line with official regulatory procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alevo found in:

A-Z Index: